Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
This article was originally published in The Pink Sheet Daily
Executive Summary
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.
You may also be interested in...
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
BioVeris Licenses Vaccine Candidates For Six Organisms From Baxter
Under the agreement, BioVeris will pay Baxter a license issue fee as well as milestone payments and royalties.